Navigation Links
GlySure CEO to Present CE Mark Trial Results at OneMedForum 2014
Date:1/7/2014

t promising microcap public companies and high growth private (pre-IPO) companies. More than 100 companies and 1,300 investors attend the annual event.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870, cjones@glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127, kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
2. PAREXEL International To Present At JP Morgan Healthcare Conference
3. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
4. Accuray to Present at JP Morgan 32nd Annual Healthcare Conference
5. Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
6. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
7. Sigma-Aldrich Corporation To Present At 32nd Annual J.P. Morgan Healthcare Conference
8. Gateway Analytical to Present Latest Research at the Drug Delivery to the Lungs Conference in Edinburg, Scotland
9. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
10. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
(Date:7/10/2014)... sit upside down forever. Nanophysics makes sure of that. Mechanics ... just published in Physical Review E . Knowledge that ... that seem to be able to sit still forever, and ... years. We will soon be able to buy smart new ... But the fact is, sooner or later the grip is ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2
... Signalife,Inc. (Amex: SGN ) announced that it ... merger or similar business combination with,Heart One Global ... to proceed with due diligence and other matters ... a new parent,company will be established by Signalife ...
... study using the CiTop™ technology in the coronary arteries. Ovalum ... today successful experiences using CiTop™ ExPander™ Guidewire in traversing chronic ... ... Rehovot , Israel (PRWEB) July 11, 2008 -- ...
... , The white blood cells in our body combat ... leukemia, the formation of white blood cells is disturbed: ... multiply out of control without fully maturing. This process ... more susceptible to infections. T-ALL, a particular form of ...
Cached Biology Technology:Signalife Board Approves Merger 2Signalife Board Approves Merger 3Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire 2Not the protein, but its location in the cell, determines the onset of leukemia 2
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
(Date:7/10/2014)... June 27, 2014  Pomerantz LLP has filed ... ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of ... States District Court, Middle District of ... of a class consisting of all persons or ... between December 17, 2013 and May 22, 2014, ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... release is available in German . ... in Freiburg have gained important insights for stem cell research ... to the development of new treatments. As Rolf Kemler,s research ... determines the length of the telomeres and a signalling pathway ...
... , Akron, Ohio, June 27, 2012 Expertise in fluid ... a new research center designed to help physicians better diagnose ... neck and shoulders. Chiari malformation is a disorder of ... brain and spinal fluid. UA engineers are able to ...
... animal scientists are working together to meet the challenges of ... experimental Biology on 28th June will demonstrate innovative techniques and ... issues, crop yields and diminishing fish stocks. , In ... the world,s four most important crops has fallen short of ...
Cached Biology News:When does a headache need an engineer to fix it? 2When does a headache need an engineer to fix it? 3
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
Economical and manually filled LN2 vacuum insulated storage container offers high capacity and low nitrogen consumption while offering convenient storage of samples....
... Transcriptase (M-MLV RT) is an RNA-dependent DNA polymerase ... long messenger RNA templates (>5kb). The enzyme is ... and consists of a single subunit with a ... of M-MLV RT is weaker than the commonly ...
Biology Products: